Recent Finacing
Recent Raise
Accuitis is a preclinical biopharmaceutical company developing topical proteasome inhibitor therapies for chronic skin and eye inflammatory diseases; lead candidate ACU-D1, discovered at Emory, targets rosacea and related conditions.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors